Introduction: Type 2 diabetes mellitus (T2DM) is associated not only with high direct healthcarecosts, but also with indirect costs, as diabeticcomplications and the disease itself result in lossof productivity. Vildagliptin is a novel dipeptidyl peptidase-4 inhibitor that is given either alone orin combination with oral hypoglycemic drugs,including metformin. The study was designedto assess the hypothesis that fixed-combinationvildagliptin/metformin improves workproductivity measured as Work Productivity and Activity Impairment (WPAI) scores. Secondary objectives were the assessment of patient satisfaction by means of the Diabetes TreatmentSatisfaction Questionnaire (DTSQs), the changein anthropometric measurements and in glucosecontrol (glycated hemoglobin [HbA1c]), and theevaluation of resource utilization (Resources Utilization Questionnaire).Methods: This study was an addendum to a mandatory, prospective, observational study carried out by the Italian Medicines Agency (AgenziaItaliana del Farmaco [AIFA]) in 49 diabetes centers in Italy. The addendum included 1,046 adult outpatients with a diagnosis of T2DM, who wereno longer responding to metformin monotherapy. Patients were observed for up to 1 year. Results: Mean activity impairment improved by40.6% (15.4 ± 17.4 vs. 26.1 ± 24.4; P < 0.0001),absenteeism by 49.9% (2.0 ± 9.4 vs. 3.8 ± 13.3;P = 0.0076), and total work productivity by 37.6%(14.9 ± 15.9 vs. 21.5 ± 24.6; P < 0.0001). Thisresulted in a reduction of the annual indirect cost due to impaired productivity of €400 perworking patient and €135 per patient in general. The DTSQ score increased by 30.2% (29.6 ±5.6 vs. 22.8 ± 6.9; P < 0.0001). The satisfaction rate increased from baseline by 44.7%; thehyperglycemia-free or almost hyperglycemia-free perception rate by 37.9%; and the hypoglycemia-free or almost hypoglycemia-free rate by 15.2%.Mean healthcare costs per patients diminishedby 19.2% in the second semester of treatment.Conclusion: This observational study suggests that the fixed combination of vildagliptin/metformin increases work productivity, reducing indirect costs, and improves quality oflife, especially in terms of perception of blood glucose variability, in patients with T2DM.
|Numero di pagine||13|
|Rivista||Advances in Therapy|
|Stato di pubblicazione||Published - 2013|
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)